These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 10233832)
21. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292 [TBL] [Abstract][Full Text] [Related]
22. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041 [TBL] [Abstract][Full Text] [Related]
23. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291 [TBL] [Abstract][Full Text] [Related]
24. Malignant progression in Barrett's esophagus: pathology and molecular biology. Mueller J; Werner M; Siewert JR Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236 [TBL] [Abstract][Full Text] [Related]
25. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552 [TBL] [Abstract][Full Text] [Related]
26. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431 [TBL] [Abstract][Full Text] [Related]
27. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754 [TBL] [Abstract][Full Text] [Related]
28. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831 [TBL] [Abstract][Full Text] [Related]
29. The diagnosis and management of Barrett's esophagus. DeMeester SR; DeMeester TR Adv Surg; 1999; 33():29-68. PubMed ID: 10572561 [TBL] [Abstract][Full Text] [Related]
30. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152 [TBL] [Abstract][Full Text] [Related]
31. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817 [TBL] [Abstract][Full Text] [Related]
33. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus. Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189 [TBL] [Abstract][Full Text] [Related]
34. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Odze RD; Lauwers GY Endoscopy; 2008 Dec; 40(12):1008-15. PubMed ID: 19065484 [TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. Dolan K; Morris AI; Gosney JR; Field JK; Sutton R J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151 [TBL] [Abstract][Full Text] [Related]
37. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment. Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044 [TBL] [Abstract][Full Text] [Related]
38. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
39. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757 [TBL] [Abstract][Full Text] [Related]
40. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma. van de Winkel A; Menke V; Capello A; Moons LM; Pot RG; van Dekken H; Siersema PD; Kusters JG; van der Laan LJ; Kuipers EJ BMC Gastroenterol; 2011 Oct; 11():108. PubMed ID: 21977915 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]